R01C:Preservation and Growth of Human Follicles (4 of 10)

R01C：人类卵泡的保存和生长（10 中的 4）

• 批准号: 7649510
• 负责人: Teresa K Woodruff
• 金额: $ 42.61万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-30 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7649510
• 关键词: Address; Age; Algorithms; Biocompatible Materials; Biological Preservation; Cancer Patient; Cancer Survivor; Clinical; Communication; Counseling; Cryopreservation; Data; Decision Making; Development; Discipline; Economics; Emergency Situation; Ethics; Failure; Family; Female; Fertility; Fertilization in Vitro; Goals; Growth; Human; In Vitro; Life; Malignant Neoplasms; Methods; Mus; Oncologist; Oocytes; Ovarian; Ovarian Follicle; Ovarian Tissue; Patient Recruitments; Patients; Pharmaceutical Preparations; Physicians; Premature Ovarian Failure; Production; Provider; Recruitment Activity; Relative (related person); Reproductive Biology; Research Proposals; Risk; Risk Assessment; Role; Science; Specialist; Staging; Steroids; System; Systemic Therapy; Technology; Testing; Time; Toxic effect; Translating; Treatment Protocols; Treatment outcome; Woman; Work; analytical method; cancer therapy; chemotherapeutic agent; chemotherapy; childhood cancer survivor; combinatorial; improved; nonhuman primate; oocyte maturation; phrases; reproductive; reproductive axis; response; Address; Age; Algorithms; Biocompatible Materials; Biological Preservation; Cancer Patient; Cancer Survivor; Clinical; Communication; Counseling; Cryopreservation; Data; Decision Making; Development; Discipline; Economics; Emergency Situation; Ethics; Failure; Family; Female; Fertility; Fertilization in Vitro; Goals; Growth; Human; In Vitro; Life; Malignant Neoplasms; Methods; Mus; Oncologist; Oocytes; Ovarian; Ovarian Follicle; Ovarian Tissue; Patient Recruitments; Patients; Pharmaceutical Preparations; Physicians; Premature Ovarian Failure; Production; Provider; Recruitment Activity; Relative (related person); Reproductive Biology; Research Proposals; Risk; Risk Assessment; Role; Science; Specialist; Staging; Steroids; System; Systemic Therapy; Technology; Testing; Time; Toxic effect; Translating; Treatment Protocols; Treatment outcome; Woman; Work; analytical method; cancer therapy; chemotherapeutic agent; chemotherapy; childhood cancer survivor; combinatorial; improved; nonhuman primate; oocyte maturation; phrases; reproductive; reproductive axis; response

Ten years ago, the phrase 'families after cancer1 for most women would have been an oxymoron if contemplated at all. Today, due to the impressive rise in young female cancer survivors, this is not only a well-used phrase, but also an issue that women increasingly want addressed. As the lexicon is being established, the boundaries are expanding to encompass the fertility needs of childhood cancer survivors for whom fertility-conserving options are limited. The role of the emerging oncofertility specialist is to navigate through the available options and provide individualized counseling to patients. To provide this kind of authoritative information to women in different age brackets, with different treatment regimens, it is necessary to evaluate the reproductive axis and its response to cancer treatment in a rigorous manner. The ability to recruit patients through the large National Physicians Cooperative (P30B) will provide sufficient power to correlate treatment and outcome data in a comprehensive and thorough manner. In Specific Aim 1, we will develop combinatorial analytical methods and a predictive algorithm to assess the Risk of Impending Premature Ovarian Failure (RIPOF, pronounced rip off) in young women treated with chemotherapeutics for their cancers. These data will improve information exchange between the provider and the patient about the risk and timeframe of impending premature ovarian failure. We will also use the established murine ovarian culture system to test a broad panel of chemotherapeutics and establish endpoints that can be used to rapidly assess the likely fertility impact of any new or existing drugs that are introduced into the oncologists' arsenal (Specific Aim 2). Therefore, the relative toxicity of new chemotherapeutic agents on in vitro follicle survival and maturation (in vitro risk, IVR) will be investigated. Finally, the major goal of the project is to develop methods to grow immature human ovarian follicles into the mature, fertilizable stage (Specific Aim 3). We will translate recent breakthroughs at the interface of material science and reproductive biology into clinically-proven technology that can provide additional fertility options to those who may lose fertility due to cancer treatment.

十年前，如果大多数女性的癌症之后的一句话的家庭将是矛盾的话，如果 根本考虑过。今天，由于年轻女性癌症幸存者的令人印象深刻的增长，这不仅是 使用良好的短语，但也是女性越来越想解决的问题。词典正在 建立的边界正在扩展，以涵盖儿童期癌症幸存者的生育需求 持有生育能力的选择有限。新兴的Oncofertility专家的作用是导航 通过可用的选择，并为患者提供个性化的咨询。提供这种 给不同年龄段的妇女的权威信息，具有不同的治疗方案，这是 以严格的方式评估生殖轴及其对癌症治疗的反应所必需的。这 通过大型国家医生合作（P30B）招募患者的能力将提供足够的 以全面而彻底的方式将治疗和结果数据相关联。在特定的目标1中， 我们将开发组合分析方法和预测算法，以评估即将来临的风险 在接受化学治疗药物治疗的年轻妇女中 他们的癌症。这些数据将改善提供者和患者之间有关的信息交换 即将发生早产卵巢衰竭的风险和时间表。我们还将使用已建立的鼠卵巢 培养系统测试一系列化学治疗剂并建立可用于用于的终点 迅速评估引入肿瘤学家的任何新药物或现有药物的可能产生影响 阿森纳（特定目标2）。因此，新化学治疗剂对体外卵泡的相对毒性 将研究生存和成熟（体外风险，IVR）。最后，该项目的主要目标是 开发方法将未成熟的人类卵巢卵泡发展成成熟的，可肥的阶段（特定目的 3）。我们将在材料科学界面和生殖生物学界面的最新突破中转化为 临床经验丰富的技术，可以为可能因由于 癌症治疗。